Bavarian Nordic AS

BAVA

Equity

ISIN DK0015998017 / Valor 944279

Nasdaq Copenhagen Equities (2025-04-08)

DKK 147.90+5.53%

Bavarian Nordic AS
UMushroom community rating:

5.00 1 votes No rating yet

NegativeNeutralPositive

About company

Bavarian Nordic AS is a company that focuses on researching, developing, and manufacturing vaccines using viral vectors to deliver antigens for infectious diseases. The company is highly specialized in this area and has a strong track record in vaccine development. With a focus on innovation and scientific expertise, Bavarian Nordic AS plays a crucial role in the fight against infectious diseases globally.

Summarized from source with an LLMView SourceSector: Technology

Revenue Performance

Bavarian Nordic A/S reported revenue of DKK 2,259 million for the first half of 2024. This performance was driven by a 15% increase in travel health revenue, which amounted to DKK 1,119 million. Additionally, public preparedness revenue was DKK 1,024 million, aligning with the company's expectations. Other revenue sources contributed DKK 116 million to the total.

Operating Profit

The operating profit (EBITDA) for Bavarian Nordic A/S in the first half of 2024 was DKK 441 million. This figure reflects the company's ongoing efforts to optimize its operations and manage costs effectively, despite the challenges faced in the global market.

Sales Milestone

Bavarian Nordic A/S achieved a significant sales milestone with its Rabipur/RabAvert and Encepur products, surpassing initial expectations. This success triggered a sales milestone payment of DKK 186 million to GSK, which is scheduled for the third quarter of 2024.

Guidance Confirmation

The company has confirmed its guidance for the full year 2024, projecting aggregated revenue at the upper end of the range, approximately DKK 5,300 million. The EBITDA is expected to be around DKK 1,350 million, with public preparedness revenue largely secured by existing contracts.

Future Outlook

Bavarian Nordic A/S is preparing to ramp up its vaccine manufacturing capacity in response to recent global health developments. The company plans to produce 10 million doses by the end of 2025, ensuring continued equitable access to its mpox vaccine. This strategic move aligns with its commitment to supporting global public health initiatives.

Summarized from source with an LLMView Source

Key figures

-1.73%1Y

-11.4%3Y

9.72%5Y

Performance

50.7%1Y

60.0%3Y

55.8%5Y

Volatility